NHLBI TOPMed - NHGRI CCDG: Genes-Environments and Admixture in Latino Asthmatics (GALA II)

This is a case-only pharmacogenetic study of bronchodilator drug response among racially admixed Latino children with asthma. Each participant had two spirometry measurements using the KoKo PFT System. With the first spirometry test, participant was administered with 4 puffs of HFA Albuterol. The second albuterol measurement was based on age, for participants under 16 years of age, additional 2 puffs were administered and for those over 16 years of age, additional 4 puffs were administered. The overall goal is to identify genetic factors which are predictive of drug response in children with asthma. The principal tools include a questionnaire and biological specimen collection. Participants are 8-21 years old at time of recruitment. Children with asthma have physician-diagnosed asthma, symptoms and medications. Comprehensive phenotypic data for GALAII study participants are available through dbGaP phs001180.]]>
TOPMed Whole Genome Sequencing Methods: Freeze 9TOPMed Whole Genome Sequencing Methods: Freeze 10Eligibility Subjects meeting the following criteria will be eligible for participation: Ages between 8 and 21 years old Parents and Grandparents of the same ethnicity [self-identified] History of asthma [physician diagnosed or currently taking asthma medication] Having experienced symptoms of coughing, wheezing or shortness of breath in the past 2 years No respiratory infections for ≥ 6 weeks No asthma exacerbations for ≥ 6 weeks ≤ 10 pack year smoking history, no smoking in the last year If pregnant, < 3rd trimester No other history of lung diseases ]]>
Time Line February 2006 - First qualifying participant Spring 2013 - Genome Wide Association Study completed December 2014 - Whole Genome Sequencing ]]>